Bio-Thera(SH:688177)2025-07-29 08:10Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between -110 million and -140 million CNY, representing a reduction in losses of 96.84 million to 126.85 million CNY compared to the same period last year [3]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -160 million and -190 million CNY, indicating a reduction in losses of 80.33 million to 110.33 million CNY [3]. - The total profit for the same period last year was -236.85 million CNY, with a net profit attributable to shareholders also at -236.85 million CNY [5]. Revenue and Expenses - The company achieved an increase in operating revenue of 20 million to 50 million CNY, primarily due to the steady growth in sales of Adalimumab injection (Geleli®) compared to the same period last year [8]. - Research and development expenses decreased by 40 million to 70 million CNY, as several R&D projects have completed global Phase III clinical trials, with BAT2206, BAT2306, and BAT2506 currently in the listing application stage [8]. - BAT2206 has received approval for market launch from the U.S. FDA, contributing to the reduction in R&D expenses [8]. Audit and Forecast Validity - The company emphasizes that the performance forecast has not been audited by certified public accountants [4]. - The forecast data is preliminary and the specific financial data will be disclosed in the official 2025 semi-annual report [10]. - The company assures that there are no significant uncertainties affecting the accuracy of this performance forecast as of the announcement date [9]. - Investors are advised to pay attention to investment risks related to the preliminary nature of the forecast data [10].